<DOC>
	<DOCNO>NCT01407822</DOCNO>
	<brief_summary>Stage IIIA NSCLC represent relatively heterogeneous group pts ipsilateral mediastinal ( N2 ) lymph node involvement . The relative role treatment modality clearly define . Concurrent chemoradiation therapy remain important treatment stage IIIA disease , treatment-related life threaten toxicity limit use . The EGFR tyrosine kinase inhibitor ( TKI ) may provide dramatic response pt pulmonary adenocarcinoma carry EGFR activate mutation metastatic setting . In OPTIMAL study , first-line erlotinib versus carboplatin/GEM advance NSCLC pt EGFR activate mutation , primary analysis show significantly prolong progressive free survival ( PFS ) erlotinib vs carboplatin/GEM ( p &lt; 0.0001 ) . The aim study investigate efficacy safety erlotinib versus GEM plus cisplatin ( GC ) neoadjuvant treatment pt stage IIIA-N2 NSCLC EGFR activate mutation explore new treatment strategy subset .</brief_summary>
	<brief_title>Erlotinib Versus Gemcitabine/Cisplatin ( Neo ) Adjuvant Treatment Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Concurrent Chemoradiation therapy remain standard treatment stage IIIA disease , treatment-related life threaten toxicity limit use pt . Tarceva monotherapy demonstrate significant improvement overall survival disease progression free survival use treatment patient metastatic NSCLC , failure least one prior chemotherapy regimen . It well tolerate without side effect usually associate chemotherapy . Based encouraging result report SLCG phase II study report efficacy Tarceva first line treatment metastatic NSCLC EGFR mutation patient would prolong overall survival , delay disease progression well tolerate , mOS reach 27 month , ORR reach 71 % . Besides , different mechanism tolerable chemo , Tarceva may provide important treatment alternative local advance pt EGFR mutation . In IPASS study ( gefitinib carboplatin/paclitaxel pulmonary adenocarcinoma first line treatment ) , subgroup 261 patient positive epidermal growth factor receptor gene ( EGFR ) mutation , progression-free survival significantly longer among received gefitinib among receive carboplatin-paclitaxel ( hazard ratio progression death , 0.48 ; 95 % CI , 0.36 0.64 ; P &lt; 0.001 ) . In OPTIMAL study ( first-line erlotinib versus carboplatin/gemcitabine Chinese advance NSCLC patient EGFR activate mutation ) , primary analysis show PFS significantly prolong erlotinib v carboplatin/paclitaxel ( 13.1months vs 4.6 month , HR 0.16 ; p &lt; 0.0001 ) . The objective response rate significantly improve erlotinib v carboplatin/paclitaxel ( 83 % vs 36 % , p=0.0000 ) , disease control rate ( CR + PR + SD ; 96 v 82 % ; p=0.002 ) . The aim study investigate efficacy safety Tarceva versus combination Gemcitabine plus Cisplatin neoadjuvant treatment patient stage IIIA- N2 NSCLC EGFR activate mutation exon 19 21 .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Written inform consent provide . Males female age ≥18 year . Able comply require protocol followup procedure , able receive oral medication . Pathologically diagnose nonsmall cell lung cancer . Diagnosed stage IIIA N2.The diagnosis standard N2 : Pts resectable stage IIIAN2 NSCLC confirm mediastinoscopy EBUS PET/CT . EGFR activate mutation exon 19 21 biopsy primary tumor N2 lymph node . Measurable disease must characterize accord RECIST 1.1 criterion . Measurable lesion define accurately measure least one dimension ( long diameter record ) ≥ 10mm spiral CT MRI scan . The measurable criterion lymph node short axis ≥ 15 mm . ECOG performance status 01 . Life expectancy ≥12 week . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L , Platelet count ≥100 x 109/L , Hemoglobin ≥9 g/dL ( may transfuse maintain exceed level ) . Adequate liver function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ≤ 2.5 x ULN subject without liver metastasis ; ≤ 5 x ULN subject liver metastasis . Adequate renal function : Serum creatinine ≤ 1.25 x ULN , creatinine clearance ≥ 60 ml/min . Female subject pregnant breastfeeding . Patients prior exposure agent direct HER axis ( e.g . erlotinib , gefitinib , cetuximab , trastuzumab ) . Patients prior chemotherapy therapy systemic antitumour therapy ( e.g . monoclonal antibody therapy ) . Resection primary malignancy . EGFR mutation ( exon 19 21 ) negative unknown . Uncontrolled central nervous system ( CNS ) metastasis . History another malignancy last 5 year exception following : Other malignancy cure surgery alone continuous diseasefree interval 5 year permit ; Cured basal cell carcinoma skin cure situ carcinoma uterine cervix permit . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal , metabolic disease ) . Known hypersensitivity Tarceva gemcitabine cisplatin . Eye inflammation eye infection fully treat condition predispose subject . Evidence disease , neurological metabolic dysfunction , physical examination laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put subject high risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>IIIA-N2</keyword>
	<keyword>Neo-adjuvant treatment</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
</DOC>